Convoy Therapeutics Appoints Clinical Advisory Board
Convoy Therapeutics Looks to Raise $27 Million
Convoy Therapeutics and Hugel Enter Co-Development Partnership
Convoy Therapeutics granted a patent for proprietary technology
Our current focus is on the development of our first two products: Khalay HA™, a cosmetic to treat fine lines and wrinkles, and CycloPsorb™, a topical formulation of Cyclosporine for the treatment of psoriasis, which is being developed via the 505(b)(2) pathway.